No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss
Outlook Therapeutics Faces Business Risks From Third-Party Manufacturing Dependencies
Outlook Therapeutics Provides ONS-5010/LYTENAVA Update
Outlook Therapeutics | 10-K: FY2024 Annual Report
Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment
Outlook Therapeutics Shares Are Trading Higher After the Company Announced a Year-over-year Increase in FY24 Eps Results.